{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:25:14Z","timestamp":1794086714391,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CB11322"],"award-info":[{"award-number":["CB11322"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CB10794"],"award-info":[{"award-number":["CB10794"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.antiviral.2026.106548","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:20Z","timestamp":1791613640000},"page":"106548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molnupiravir, first small molecule therapeutic to demonstrate therapeutic efficacy against Venezuelan equine encephalitis virus in the cynomolgus macaque model"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-8966","authenticated-orcid":false,"given":"Christina L.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-8983","authenticated-orcid":false,"given":"Lisa","family":"Pieterse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5232-8110","authenticated-orcid":false,"given":"Ashley E.","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2605-7965","authenticated-orcid":false,"given":"Elaine S.","family":"Cerchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6940-9544","authenticated-orcid":false,"given":"Franco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-2443","authenticated-orcid":false,"given":"Weam I.","family":"Zaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby J.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-0595","authenticated-orcid":false,"given":"Sarah K.","family":"Cudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9967-3670","authenticated-orcid":false,"given":"William A.","family":"Baskerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-6430","authenticated-orcid":false,"given":"Sarah","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Matthew","family":"Meinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.antiviral.2026.106548_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/infdis\/jiae445","article-title":"Retrospective analysis of blood biomarkers of neurological injury in human cases of viral infection and bacterial sepsis","volume":"231","author":"Bartlett","year":"2025","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106548_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/v10040147","article-title":"Human-like neutralizing antibodies protect mice from aerosol exposure with Western equine encephalitis virus","volume":"10","author":"Burke","year":"2018","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.antiviral.2026.106548_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008157","article-title":"Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure","volume":"15","author":"Burke","year":"2019","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.antiviral.2026.106548_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/v14071502","article-title":"Efficacy of Western, Eastern, and Venezuelan equine encephalitis (WEVEE) virus-replicon particle (VRP) vaccine against WEEV in a non-human primate animal model","volume":"14","author":"Burke","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.antiviral.2026.106548_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/v15122351","article-title":"Defining the cynomolgus macaque (Macaca fascicularis) animal model for aerosolized Venezuelan equine encephalitis: importance of challenge dose and viral subtype","volume":"15","author":"Burke","year":"2023","journal-title":"Viruses"},{"issue":"812","key":"10.1016\/j.antiviral.2026.106548_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adt9853","article-title":"High binding potency overcomes the requirement of Fc effector functions for broadly reactive anti-alphavirus antibodies","volume":"17","author":"Callahan","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s43856-023-00383-w","article-title":"Transporter modulation of molnupiravir and its metabolite beta-D-N4-hydroxycytidine across the blood-brain barrier in a rat","volume":"3","author":"Chang","year":"2023","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib8","first-page":"50","article-title":"The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalomyelitis virus in normal and operated Macaca rhesus monkeys. I. Results of virological examination","volume":"17","author":"Danes","year":"1973","journal-title":"Acta Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib9","first-page":"57","article-title":"The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalomyelitis virus in normal and operated Macaca rhesus monkeys. II. Results of histological examination","volume":"17","author":"Danes","year":"1973","journal-title":"Acta Virol."},{"issue":"46","key":"10.1016\/j.antiviral.2026.106548_bib10","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2010.09.005","article-title":"Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates","volume":"28","author":"Dupuy","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/CVI.00030-11","article-title":"A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates","volume":"18","author":"Dupuy","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106548_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of beta-d-N(4)-Hydroxycytidine as a novel inhibitor of Chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106548_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/toxsci\/kfae112","article-title":"Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir","volume":"202","author":"Escobar","year":"2024","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01875-25","article-title":"Demonstration of in vivo efficacy, cryo-EM-epitope identification, and breadth of two anti-alphavirus bispecific single domain antibodies","volume":"100","author":"Gardner","year":"2026","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12941-020-00360-4","article-title":"Venezuelan equine encephalitis virus: the problem is not over for tropical America","volume":"19","author":"Guzman-Teran","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"10","key":"10.1016\/j.antiviral.2026.106548_bib16","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cts.13602","article-title":"Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants","volume":"16","author":"Iwamoto","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106548_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s44298-025-00160-7","article-title":"Sequelae of viral CNS infections including outcomes, mechanisms, and knowledge gaps","volume":"3","author":"Kelly","year":"2025","journal-title":"Npj Viruses"},{"issue":"492","key":"10.1016\/j.antiviral.2026.106548_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav3113","article-title":"A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates","volume":"11","author":"Ko","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"818","key":"10.1016\/j.antiviral.2026.106548_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv7079","article-title":"An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques","volume":"17","author":"Lam","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.antiviral.2026.106548_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009946","article-title":"Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus","volume":"18","author":"Ma","year":"2022","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106548_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13732","article-title":"Molnupiravir: mechanism of action, clinical, and translational science","volume":"17","author":"Maas","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"7","key":"10.1016\/j.antiviral.2026.106548_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkad132","article-title":"Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"78","author":"Malin","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2026.106548_bib23","series-title":"FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR LAGEVRIO\u2122 (Molnupiravir) CAPSULES","author":"Merck","year":"2024"},{"issue":"2","key":"10.1016\/j.antiviral.2026.106548_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/v15020413","article-title":"Advances in the development of small molecule antivirals against equine encephalitic viruses","volume":"15","author":"Ogorek","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2026.106548_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of Molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.antiviral.2026.106548_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/mps7060105","article-title":"Formalin and 2.5% Glutaraldehyde\/2% paraformaldehyde in 0.1 M cacodylate buffer inactivation protocols to ensure the proper fixation of positive sense RNA viruses and genomic material prior to removal from containment","volume":"7","author":"Panny","year":"2024","journal-title":"Methods Protoc."},{"issue":"9\u201310","key":"10.1016\/j.antiviral.2026.106548_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0264-410X(97)00192-8","article-title":"Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates","volume":"16","author":"Pratt","year":"1998","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.antiviral.2026.106548_bib29","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.antiviral.2026.106548_bib30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1086\/382281","article-title":"Aerosol infection of cynomolgus macaques with enzootic strains of venezuelan equine encephalitis viruses","volume":"189","author":"Reed","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"24","key":"10.1016\/j.antiviral.2026.106548_bib31","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.antiviral.2026.106548_bib32","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1128\/JVI.01406-14","article-title":"Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses","volume":"88","author":"Reed","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106548_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3389\/fmicb.2016.00959","article-title":"Neurological sequelae resulting from encephalitic alphavirus infection","volume":"7","author":"Ronca","year":"2016","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003797","article-title":"IRES-containing VEEV vaccine protects cynomolgus macaques from IE Venezuelan equine encephalitis virus aerosol challenge","volume":"9","author":"Rossi","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.30802\/AALAS-CM-18-000027","article-title":"Comparison of Aerosol- and percutaneous-Acquired Venezuelan equine encephalitis in humans and nonhuman Primates for suitability in predicting clinical efficacy under the animal rule","volume":"68","author":"Rusnak","year":"2018","journal-title":"Comp. Med."},{"issue":"9","key":"10.1016\/j.antiviral.2026.106548_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/v11090807","article-title":"Approach to strain selection and the propagation of viral stocks for Venezuelan equine encephalitis virus vaccine efficacy testing under the animal rule","volume":"11","author":"Rusnak","year":"2019","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.antiviral.2026.106548_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.antiviral.2026.106548_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104875","article-title":"Comparative pathology study of Venezuelan, eastern, and western equine encephalitis viruses in non-human primates","volume":"182","author":"Smith","year":"2020","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0300985810372508","article-title":"Review paper: pathology of animal models of alphavirus encephalitis","volume":"47","author":"Steele","year":"2010","journal-title":"Vet. Pathol."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106548_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01965-17","article-title":"beta-d-N(4)-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106548_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1514940","article-title":"Neurological manifestations of encephalitic alphaviruses, traumatic brain injuries, and organophosphorus nerve agent exposure","volume":"18","author":"VanderGiessen","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.antiviral.2026.106548_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106186","article-title":"Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo","volume":"239","author":"Verwimp","year":"2025","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106548_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020193","article-title":"Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection","volume":"14","author":"Woodson","year":"2025","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/j.antiviral.2026.106548_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000944","article-title":"Molnupiravir is effective against hepatitis E virus infection in an animal model","volume":"10","author":"Wu","year":"2026","journal-title":"Hepatol. Commun."},{"issue":"3\u20134","key":"10.1016\/j.antiviral.2026.106548_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet. Microbiol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422600207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422600207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:21:33Z","timestamp":1794086493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635422600207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S016635422600207X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106548","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molnupiravir, first small molecule therapeutic to demonstrate therapeutic efficacy against Venezuelan equine encephalitis virus in the cynomolgus macaque model","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106548"}}